Thomas J. Riga - 30 Jan 2023 Form 4 Insider Report for SPECTRUM PHARMACEUTICALS INC

Reporting relationship: CEO & President, Director
Issuer ticker: N/A
Reported as of: 30 Jan 2023
Net transaction value: -$108,647
SEC form: 4
Accepted by SEC: 01 Feb 2023, 16:10:24 UTC
Prior SEC filing: 05 Jan 2023
Next SEC filing: 24 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Keith M. McGahan, Attorney-in-Fact for Thomas J. Riga

Key filing fact

Thomas J. Riga filed Form 4 for SPECTRUM PHARMACEUTICALS INC on 01 Feb 2023.

Key facts

This page summarizes Thomas J. Riga's Form 4 filing for SPECTRUM PHARMACEUTICALS INC.
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 01 Feb 2023, 16:10.

Change

Previous filing in this sequence was filed on 05 Jan 2023.
Current net transaction value: -$108,647.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPPI transaction

Common Stock, $0.001 par value

Sale

Transaction value: $37,748
Shares: -69,389
Change %: -3.3%
Price: $0.5440
Shares after: 2,008,022
Date: 30 Jan 2023
Ownership: Direct
Footnotes: F1

SPPI transaction

Common Stock, $0.001 par value

Sale

Transaction value: $70,900
Shares: -107,424
Change %: -5.3%
Price: $0.6600
Shares after: 1,900,598
Date: 31 Jan 2023
Ownership: Direct
Footnotes: F1, F2

SPPI holding

Common Stock, $0.001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 14,139
Date: 30 Jan 2023
Ownership: By 401(k) plan

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer.

Footnote F2

This transaction was executed in multiple trades at prices that when rounded to the nearest cent were equal to $0.66. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.